BioMarin Pharmaceutical Shares Outstanding 2006-2021 | BMRN

BioMarin Pharmaceutical shares outstanding history from 2006 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • BioMarin Pharmaceutical shares outstanding for the quarter ending June 30, 2021 were 0.185B, a 2.6% increase year-over-year.
  • BioMarin Pharmaceutical 2020 shares outstanding were 0.192B, a 7.06% increase from 2019.
  • BioMarin Pharmaceutical 2019 shares outstanding were 0.179B, a 1% increase from 2018.
  • BioMarin Pharmaceutical 2018 shares outstanding were 0.177B, a 1.63% increase from 2017.
BioMarin Pharmaceutical Annual Shares Outstanding
(Millions of Shares)
2020 192
2019 179
2018 177
2017 174
2016 166
2015 160
2014 146
2013 138
2012 120
2011 112
2010 126
2009 100
2008 104
2007 96
2006 85
2005 69
BioMarin Pharmaceutical Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 185
2021-03-31 184
2020-12-31 192
2020-09-30 198
2020-06-30 181
2020-03-31 187
2019-12-31 179
2019-09-30 186
2019-06-30 179
2019-03-31 178
2018-12-31 177
2018-09-30 177
2018-06-30 177
2018-03-31 176
2017-12-31 174
2017-09-30 175
2017-06-30 174
2017-03-31 173
2016-12-31 166
2016-09-30 168
2016-06-30 163
2016-03-31 162
2015-12-31 160
2015-09-30 161
2015-06-30 160
2015-03-31 158
2014-12-31 146
2014-09-30 159
2014-06-30 146
2014-03-31 144
2013-12-31 138
2013-09-30 141
2013-06-30 140
2013-03-31 128
2012-12-31 120
2012-09-30 123
2012-06-30 118
2012-03-31 115
2011-12-31 112
2011-09-30 112
2011-06-30 111
2011-03-31 111
2010-12-31 126
2010-09-30 131
2010-06-30 102
2010-03-31 104
2009-12-31 100
2009-09-30 102
2009-06-30 101
2009-03-31 100
2008-12-31 104
2008-09-30 103
2008-06-30 104
2008-03-31 104
2007-12-31 96
2007-09-30 96
2007-06-30 96
2007-03-31 95
2006-12-31 85
2006-09-30 86
2006-06-30 85
2006-03-31 75
2005-12-31 69
2005-09-30 72
2005-06-30 65
2005-03-31 65
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $14.415B $1.860B
BioMarin Pharmaceutical Inc. is a developer of carbohydrate enzyme therapies for debilitating, life-threatening, chronic genetic disorders and other diseases and conditions. The company completed a six-month evaluation of patients being treated with BioMarin's lead product, BM101, for the treatment of mucopolysaccharidosis-I, or MPS-I. Patients were treated with BM101 as part of a pivotal clinical trial completed to determine the safety and efficacy of the drug in humans.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $132.971B 8.85
Bio-Rad Laboratories (BIO.B) United States $22.624B 48.22
QIAGEN (QGEN) Netherlands $12.001B 20.32
Biohaven Pharmaceutical Holding (BHVN) United States $8.691B 0.00
Emergent Biosolutions (EBS) United States $2.870B 6.92
Arcus Biosciences (RCUS) United States $2.690B 0.00
Myovant Sciences (MYOV) United Kingdom $2.182B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.045B 0.00
Zymeworks (ZYME) Canada $1.373B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.442B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29